Discovery of novel antibacterials

Expert Opinion on Drug Discovery

Volumn 5, Issue 2, 2010, Pages 145-154

  Miller, J Richard ^a,b   Waldrop, Grover L ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b PFIZER INC   (United States)

Author keywords

Antibacterials; Antibiotics; Fragment based drug design; Genomics; High throughput screening; Natural products; Resistance; Structure based drug design; Virtual screening

Indexed keywords

ANTIBIOTIC AGENT; BACITRACIN; BACTERIAL ENZYME; BACTERIAL PROTEIN; BETA LACTAM ANTIBIOTIC; CARRIER PROTEIN; CEPHALOSPORIN DERIVATIVE; DAPTOMYCIN; ENZYME INHIBITOR; ERYTHROMYCIN; FATTY ACID SYNTHASE INHIBITOR; FTSZ PROTEIN; GYRASE INHIBITOR; LINEZOLID; METICILLIN; NATURAL PRODUCT; OXAZOLE DERIVATIVE; PENICILLIN G; PLATENSIMYCIN; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEIN FTSA; PROTEIN LOLA; PROTEIN ZIPA; PYRITHIAMINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TRIMETHOPRIM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; DISEASE MODEL; DRUG DESIGN; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; FRAGMENT BASED DRUG DESIGN; GENOMICS; HIGH THROUGHPUT SCREENING; HOSPITAL INFECTION; HUMAN; INFECTION; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; RIBOSWITCH; RNA INTERFERENCE; STAPHYLOCOCCUS INFECTION; STRUCTURE ANALYSIS;

EID: 75449086103     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440903493449     Document Type: Review

References (87)

1. Sneader W. Drug discovery: a history. Wiley, West Sussex, England; 2005
2. Palumbi SR. Humans as the world's greatest evolutionary force. Science 2001;293:1786-1790
3. Levy SB. Antibiotic resistance-the problem intensifies. Adv Drug Deliv Rev 2005;57:1446-1450
4. Livermore DM. Has the era of untreatable infections arrived? J Antimicrob Chemother 2009;64(Suppl 1):i29-36
5. Talbot GH, Bradley J, Edwards JE, et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-668 (Pubitemid 43271379)
6. Marshall E. Trench warfare in a battle with TB. Science 2008;321:362-364
7. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66:1022-1037
8. Singh SB, Barrett JF. Empirical antibacterial drug discovery-foundation in natural products. Biochem Pharm 2006;71:1006-1015
9. Clardy J, Fischbach MA, Walsh CT. New antibiotics from bacterial natural products. Nat Biotechnol 2006;24:1541-1550
10. Torsvik V, Øvreås L, Thingstad TF. Prokaryotic diversity-magnitude, dynamics, and controlling factors. Science 2002;296:1064-1066
11. Pace NR. A molecular view of microbial diversity and the biosphere. Science 1997;276:734-740
12. Harvey A. Strategies for discovering drugs from previously unexplored natural products. Drug Discov Today 2000;5:294-300
13. Handelsman J. Metagenomics: application of genomics to uncultured microorganisms. Micro Mol Biol Rev 2004;68:669-685
14. Charest MG, Lerner CD, Brubaker JD, et al. A convergent enantioselective route to structurally diverse 6-deoxytetracycline antibiotics. Science 2005;308:395-398
15. Walsh C. Antibiotics: actions, origins, resistance. ASM Press: Washington DC; 2003
16. Reeves CD. The enzymology of combinatorial biosynthesis. Crit Rev Biotechnol 2003;23:95-147
17. Fu X, Albermann C, Jiang J, et al. Antibiotic optimization via in vitro glycorandomization. Nat Biotechnol 2003;21:1467-1469
18. Griffith BR, Langenhan JM, Thorson JS. Sweetening' natural products via glycorandomization. Curr Opin Biotechnol 2005;16:622-630
19. Drlica K, Zhao X. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev 1997;61:377-392
20. Laponogov I, Sohi MK, Veselkov DA, et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol 2009;16:667-669
21. Bradbury BJ, Pucci MJ. Recent advances in bacterial topoisomerase inhibitors. Curr Opin Pharmacol 2008;8:574-581
22. Miller AA, Bundy GL, Mott JE. Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors. Antimicrob Agents Chemother 2008;52:2806-2812
23. Long DD, Aggen JB, Chinn J, et al. Exploring the positional attachment of glycopeptide/beta-lactam heterdimers. J Antibiot 2008;61:603-614
24. Brötz-Oesterhelt H, Brunner NA. How many modes of action should an antibiotic have? Curr Opin Pharmacol 2008;8:564-573
25. Brown ED, Wright GD. New targets and screening approaches in antimicrobial drug discovery. Chem Rev 2005;105:759-774
26. Walsh C. Where will new antibiotics come from? Nat Rev Microbiol 2003;1:65-69
27. Von Nussbaum F, Brands M, Hinzen B, et al. Antibacterial natural products in medicinal chemistry-exodus or revival? Angew Chem Int Ed 2006;45:5072-5129
28. Bumann D. Has nature already identified all useful antibacterial targets? Curr Opin Microbiol 2008;11:387-392
29. Haydon DJ, Stokes NR, Ure R, et al. An inhibitor of FtsZ with potent and selective anti-staphylococcal activity. Science 2008;321:1673-1675
30. Pathania R, Zlitni S, Barker C, et al. Chemical genomics in escherichia coli identifies an inhibitor of bacterial lipoprotein targeting. Nat Chem Biol 2009;5:849-856
31. Blount KF, Breaker RR. Riboswitches as antibacterial drug targets. Nat Biotechnol 2006;24:1558-1564
32. Sudarsan N, Cohen-Chalamish S, Nakamura S, et al. Thiamine pyrophosphate riboswitches are targets for the antimicrobial compound pyrithiamine. Chem Biol 2005;12:1325-1335
33. Black MT, Hodgson J. Novel target sites in bacteria for overcoming antibiotic resistance. Adv Drug Deliv Rev 2005;57:1528-1538
34. Pucci MJ. Use of genomics to select antibacterial targets. Biochem Pharmacol 2006;71:1066-1072
35. Akerley BJ, Rubin EJ, Camilli A, et al. Systematic identification of essential genes by in vitro mariner mutagenesis. Proc Natl Acad Sci USA 1998;95:8927-8932
36. Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Revs Drug Discov 2007;6:29-40
37. Mochalkin I, Miller JR, Narasimhan L, et al. Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches. ACS Chem Biol 2009;4:473-483
38. Jacobs MA, Alwood A, Thaipisuttikul I, et al. Comprehensive transposon mutant library of pseudomonas aeruginosa. Proc Natl Acad Sci USA 2003;100:14339-14344
39. Payne DJ, Wallis NG, Gentry DR, et al. The impact of genomics on novel antibacterial targets. Curr Opin Drug Discov Devel 2000;3:177-190
40. Campbell JW, Cronan JE. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu Rev Microbiol 2001;55:305-332
41. Zhang YM, White SW, Rock CO. Inhibiting bacterial fatty acid synthesis. J Biol Chem 2006;281:17541-17544
42. Miller JR, Dunham S, Mochalkin I, et al. A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc Natl Acad Sci USA 2009;106:1737-1742
43. Wang J, Soisson SM, Young K, et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006;44:358-361
44. Freiberg C, Brunner NA, Schiffer G, et al. Identification and characterization of the first class of potent bacterial acetyl-coA carboxylase inhibitors with antibacterial activity. J Biol Chem 2004;279:26066-26073
45. Cheng CC, Shipps GW, Yang Z, et al. Discovery and optimization of antibacterial AccC inhibitors. Bioorg Med Chem Lett. In press, doi:10.1016/j. bmcl.2009.10.057
46. Brinster S, Lamberet G, Staels B, et al. Type II fatty acid synthesis is not a suitable antibiotic target for grampositive pathogens. Nature 2009;458:83-86
47. Mahajan-Miklos S, Tan M-W, Rahme LG, et al. Molecular mechanisms of bacterial virulence elucidated using a pseudomonas aeruginosa-caenorhabditis elegans pathogenesis model. Cell 1999;96:47-56
48. Moy TI, Conery AL, Larkins-Ford J, et al. High-throughput screen for novel antimicrobials using a whole animal infection model. ACS Chem Biol 2009;4:527-533
49. Hogan DA, Kolter R. Pseudomonas-candida interactions: an ecological role for virulence factors. Science 2002;296:2229-2232
50. Van der Sar AM, Appelmelk BJ, Vandenbroucke-Grauls CMJE, et al. A star with stripes: zebrafish as an infection model. Trends Microbiol 2004;12:451-457
51. Cossart P, Jonquières R. Sortase, a universal target for therapeutic agents against Gram-positive bacteria? Proc Natl Acad Sci USA 2000;97:5013-5015
52. Waters CM, Bassler BL. Quorom sensing: cell-to-cell communication in bacteria. Annu Rev Cell Dev Biol 2005;21:319-346
53. O'Shea R, Moser HE. Physicochemical properties of antibacterial compounds: implications for drug discovery. J Med Chem 2008;51:2871-2878
54. Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-23
55. Sandy M, Butler A. Microbial iron acquisition: marine and terrestrial siderophores. Chem Rev 2009;109:4580-4595
56. Girijavallabhan V, Miller MJ. Therapeutic uses of iron (III) chelators and their antimicrobial conjugates. In: Crosa JH, Mey AR, Payne SM, editors, Iron transport in bacteria. ASM Press: Washington, DC; 2004. p. 413-433
57. Zurenko GE, Truesdell SE, Yagi BH, et al. In vitro antibacterial activity and interactions with b-lactamases and penicillin-binding proteins of the new monocarbam antibiotic u-78608. Antimicrob Agents Chemother 1990;34:884-888
58. Sykes RB, Koster WH, Bonner DP. The new monobactams: chemistry and biology. J Clin Pharmacol 1988;28:113-119
59. Desarbre E, Page MGP. Combination medicaments for treating bacterial infections. WO2008116813; 2008
60. Desarbre E, Gaucher B, Page MGP, Roussel P. Useful combinations of monobactam antibiotics with beta-lactamase inhibitors. WO2007065288; 2007
61. Barker JJ. Antibacterial drug discovery and structure-based design. Drug Discov Today 2006;11:391-404
62. Reck F, Zhou F, Girardot M, et al. Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A. J Med Chem 2005;48:499-506
63. McInnes C. Virtual screening strategies in drug discovery. Curr Opin Chem Biol 2007;11:494-502
64. Rush TS, Grant JA, Mosyak L, et al. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J Med Chem 2005;48:1489-1495
65. Douguet D. Ligand-based approaches in virtual screening. Curr Comput Aided Drug Des 2008;4:180-190
66. Congreve M, Chessari G, Tisi D, et al. Recent developments in fragment-based drug discovery. J Med Chem 2008;51:3661-3680
67. Alex AA, Flocco MM. Fragment-based drug discovery: what has it achieved so far? Curr Top Med Chem 2007;7:1544-1567
68. Fattori D. Molecular recognition: the fragment approach in lead generation. Drug Discov Today 2004;9:229-238
69. Hopkins AL. Ligand efficiency: a useful metric for lead selection. Drug Discov Today 2004;9:430-431
70. Jhoti H, Cleasby A, Verdonk M, Williams G. Fragment-based screening using X-ray crystallography and NMR spectroscopy. Curr Opin Chem Biol 2007;11:485-493
71. Mayer MB, Mayer B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew Chem Int Ed 1999;38:1784-1788
72. Dalvit C, Fogliatto G, Stewart A, et al. WaterLOGSY as a method for primary NMR screening: Practical aspects and range of applicability. J Biol Mol NMR 2001;21:349-359
73. Hubbard RE. Fragment approaches in structure-based drug discovery. J Synchrotron Radiat 2008;15:227-230
74. Makara GM, Athanasopoulos J. Improving success rates for lead generation using affinity binding technologies. Curr Opin Biotechnol 2005;16:666-673
75. Siegel G, Eiso A, Schultz J. Integration of fragment screening and library design. Drug Discov Today 2007;12:1032-1039
76. Boehm H-J, Boehringer M, Bur D, et al. Novel Inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem 2000;43:2664-2674
77. Oblak M, Grdadolnik SG, Kotnik M, et al. In silico fragment-based discovery of indolin-2-one analogues as potent DNA gyrase inhibitors. Bioorg Med Chem Lett 2005;15:5207-5210
78. Perkins R, Fang H, Tony W, Welsh WJ. Quantitative structure-activity relationship methods: perspectives on drug discovery and toxicology. Environ Toxicol Chem 2003;22:1666-1679
79. Prado-Prado FJ, Gonzalez-Diaz H, Santana L, Uriarte E. Unified QSAR approach to antimicrobials. Part 2: predicting activity against more than 90 different species in order to halt antibacterial resistance. Bioorg Med Chem 2007;15:897-902
80. Gonzalez-Diaz H, Prado-Prado F, Ubeira FM. Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. Curr Top Med Chem 2008;8:1676-1690
81. Cai H, Rose K, Liang L-H, et al. Development of a liquid chromatography/ mass spectrometry-based drug accumulation assay in pseudomonas aeruginosa. Anal Biochem 2009;385:321-325
82. Piddock LJV, Jin YF, Griggs DJ. Effect of hydrophobicity and molecular mass on the accumulation of fluoroquinolones by Staphylococcus aureus. J Antimicrob Chemother 2001;47:261-270
83. Moreau N, Lacroix P, Fournel L. Antibiotic uptake by bacteria as measured by partition in polymer aqueous phase systems. Anal Biochem 1984;141:94-100
84. Piddock LJV, Johnson MM. Accumulation of 10 fluoroquinolones by wild-type or efflux mutant streptococcus pneumoniae. Antimicrob Agents Chemother 2002;46:813-820
85. Piddock LJV, Jin YF, Ricci V, Asuquo AE. Quinolone accumulation by pseudomonas aeruginosa, staphylococcus aureus and escherichia coli. J Antimicrob Chemother 1999;43:61-70
86. Murakami S, Nakashima R, Yamashita E, et al. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 2006;443:173-179
87. Kamicker BJ, Sweeney MT, Kaczmarek F, et al. Bacterial efflux pump inhibitors. In: Champney WS, editor, New antibiotic targets. Methods in molecular medicine (Volume 142). Humana Press, Totowa, NJ; 2008. p. 187-204